New England Biolabs and Touchlight Launch Cell-Free DNA Synthesis Kit to Accelerate Gene Therapy Development
Key Insights
New England Biolabs (search) and Touchlight (search) have released the EnClose Cell-free dbDNA Synthesis Kit, enabling benchtop enzymatic production of doggybone DNA (search) in a single day.
The kit provides a cell-free alternative to traditional plasmid DNA (search) manufacturing, eliminating bacterial fermentation requirements and reducing development timelines by months.
The doggybone DNA (search) technology is free of bacterial sequences and antibiotic resistance genes, offering improved safety profiles and regulatory compliance for gene therapies (search).
New England Biolabs (search) (NEB) and Touchlight (search) have announced the commercial launch of the EnClose Cell-free dbDNA Synthesis Kit, a breakthrough benchtop solution that enables rapid enzymatic production of doggybone DNA (search) (dbDNA) for nucleic acid therapeutic development. The collaboration addresses a critical manufacturing bottleneck that has historically slowed the development of gene therapies (search), mRNA vaccines (search), and other advanced therapeutics.
Addressing Manufacturing Bottlenecks in Gene Therapy
Traditional plasmid DNA (search) manufacturing has emerged as a significant constraint in advanced therapy development, requiring complex bacterial fermentation processes, extensive cell banking, and extended lead times that can delay clinical progression. The new kit offers researchers a streamlined alternative that bypasses these bacterial-based production challenges.
"Traditional plasmid DNA (search) manufacturing is a significant bottleneck in advanced therapies development, often requiring large-scale fermentation, cell banking, and long lead times that can slow the path to the clinic," said Dr. Ashley Luck, Associate Director of Applications and Development at NEB. "We're thrilled to offer a cell-free alternative that allows researchers to bypass these complex bacterial processes. This kit enables the rapid screening and production of high-purity DNA templates right at the benchtop, cutting months off the development timeline for mRNA vaccines (search) and gene therapies (search)."
Technical Advantages of Doggybone DNA Technology
The EnClose kit leverages Touchlight (search)'s proprietary doggybone DNA (search) technology, which produces linear, covalently closed, double-stranded DNA through an optimized enzymatic workflow. This approach enables scientists to generate high yields of closed-ended DNA in a single day, representing a substantial improvement over traditional manufacturing timelines.
Unlike conventional plasmid DNA (search), dbDNA is completely free of bacterial sequences and antibiotic resistance genes, addressing key safety concerns and simplifying regulatory compliance pathways. The technology demonstrates linear scalability from research applications through commercial production, making it particularly suitable for viral vector manufacturing including adeno-associated virus (search) (AAV (search)) and lentiviral (LV) vectors.
The enzymatic synthesis process excels at producing difficult DNA sequences that are often unstable in bacterial cultures, including long poly(A) tails and viral inverted terminal repeats. This capability expands the range of therapeutic constructs that can be efficiently manufactured for applications in non-viral gene therapy, mRNA therapeutics, and gene editing systems.
Expanding Access to Advanced DNA Manufacturing
The collaboration represents a strategic effort to democratize access to advanced DNA manufacturing technologies. Dr. Tommy Duncan, Chief Business Officer at Touchlight (search), emphasized the significance of making dbDNA technology directly available to researchers.
"Collaborating with NEB allows us to significantly broaden the accessibility of our technology, directly into the hands of researchers for the first time," Duncan said. "By combining our proprietary dbDNA technology with NEB's expertise in enzymology, we've optimized a workflow that allows scientists to screen constructs and prototype high-throughput designs rapidly, before moving on to larger-scale manufacturing."
Supporting the Nucleic Acid Therapeutic Pipeline
The launch aligns with NEB's broader commitment to supporting RNA- and DNA-based therapy development through its expanding portfolio of specialized reagents and kits. The company's strategy focuses on providing comprehensive solutions that support customers from discovery research through commercialization phases.
Touchlight (search) brings significant regulatory experience to the collaboration, having received FDA Drug Master File acceptance in 2022 and achieving the world's first cell-free DNA GMP license in 2025. The company's enzymatic DNA technology has already supported multiple client products that have advanced to clinical trials, demonstrating the platform's readiness for therapeutic applications.
The EnClose Cell-free dbDNA Synthesis Kit represents a convergence of enzymatic expertise and proprietary DNA technology designed to accelerate the development of next-generation genetic medicines. By eliminating traditional bacterial manufacturing constraints, the platform positions researchers to more rapidly advance therapeutic candidates from concept to clinic.